Lentinan Attenuates Experimental Atherosclerosis by Regulating Macrophage HCK/GUSB Expression and Amino Acid Metabolic Remodeling

Cardiovascular Drugs and Therapy · Published 2026-08-05 · DOI 10.1007/s10557-026-07925-z

Authors (6)

Guoling Rong, Jiaolong Yu, Cai Jing, Lili Liu, Bingguang Zhong, Runwen Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rong, G., Yu, J., Jing, C., et al. (2026). Lentinan Attenuates Experimental Atherosclerosis by Regulating Macrophage HCK/GUSB Expression and Amino Acid Metabolic Remodeling. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-026-07925-z

Related articles

• Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Circulating Circ_0089762 Predicts Adverse Outcomes in Acute Myocardial Infarction Via Regulating miR‑938/STAT3‑Mediated Endothelial Dysfunction · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Guideline-directed Low-density Lipoprotein Cholesterol Management After Acute Coronary Syndrome in Patients With Mental Illness: a Population-based Study · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Reflections on Oral Beta Blocker Therapy and Long-term Outcomes after Myocardial Infarction in Preserved Left Ventricular Function · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Sennoside A Ameliorates Myocardial Fibrosis After Myocardial Infarction by Binding to KDM4B and Regulates IRX2 Expression · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Cellular Senescence in Diabetic Cardiomyopathy: Mechanistic Insights and Therapeutic Perspectives · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Aspirin Instead of Clopidogrel after Percutaneous Coronary Intervention in Atrial Fibrillation: More than just an Option · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Comparing the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guideline: Convergences, Divergences, and Practical Implications · Cardiovascular Drugs and Therapy · 2026 · Same journal